CME
Expires
Claim CME Credit

CME

 

 

ACCME creditThis program provides an in-depth look at atrial shunts as a treatment option for HFpEF within the context of current medical therapies. Discussions of relevant measures of successful treatment, including hemodynamic measures and clinical outcomes. Finally, a comparison of devices under investigation will be provided.

CME Accreditation and Designation

The Cardiovascular Research Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cardiovascular Research Foundation designates this activity for a maximum of 1.0 AMA PRA Category 1 Credits™ for physicians. Physicians can claim credit commensurate with the extent of their participation in the activity.

Participants will earn MOC points equivalent to the number of CME credits claimed for the activity. Successful completion of this CME activity enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM)Maintenance of Certification (MOC) program.

It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting American Board of Internal Medicine (ABIM) MOC points.

Activity Evaluation

Evaluation by questionnaire will address content, presentation effectiveness, possible bias, and future educational needs.

Learner Objectives:

After participating in this program, learners should be able to:

• Describe current guideline-directed medical therapies (GDMT) for patients with HFpEF.
• Be able to quantify the annual rates of heart failure hospitalizations and mortality in HFpEF patients despite GDMT.
• Summarize the current state of knowledge of how interatrial shunts impact right ventricular function.
• Describe why work-normalized pulmonary capillary pressure is of interest in the evaluation of exercise and hemodynamics in response to a therapy for HFpEF.
• Describe potential differences (hemodynamic and safety) between interatrial versus coronary sinus shunting devices.

 

THT 2025 is designed for a multidisciplinary audience that includes anyone interested in heart failure management and a comprehensive overview of existing and investigational interventions. This includes:
• Heart failure specialists (fellows, nurses, physicians, physician assistants, and research coordinators)
• Cardiac imaging specialists
• Cardiac and vascular surgeons
• Clinical cardiologists
• Fellows in interventional cardiovascular medicine and related fields
• Industry professionals
• Interventional cardiologists
• Medical device experts
• Nurse practitioners
• Physician assistants
• Research scientists

 

 

Disclosure Statement

In accordance with the appropriate accrediting bodies, all planners, teachers, and authors with control over activity content are required to disclose to the provider any relevant financial relationships within the last 24 months with ineligible companies.

Accredited providers are required to provide this information to learners before the start of an activity. Discussion of off-label product usage during live cases is made at the sole discretion of the faculty. Off-label product discussion and usage are not endorsed by the Cardiovascular Research Foundation or the conference directors of this activity.

Faculty and Reviewer Disclosures

Faculty
Full Name		 Disclosure of Relevant
Financial Relationship		 Nature of Financial Relationships Individual's Role(s)
in Activity		 Mitigation Methods
Butler, Javed Yes Consultant Fee/Honoraria/Speaker’s Bureau - Abbott; American Regent; Amgen; Applied Therapeutic,; AstraZenca; Bayer AG; Boehringer Ingelheim; Bristol-Myers Squibb; Cardiac Dimension; CVRx; Cardior; Cytokinetics; Daxor Edwards,; Element Science; Impluse Dynamics; Inventiva; Lexicon; Lilly; Imbria; LivaNova; Janssen Pharmaceuticals; Medtronics; Merck/Schering Plough; Occlutech; Owkin; novartis; Pfizer; Novo Nordisk; Pharmacosmos; Pharmain; Prolaio; Roche; Secretome; Sequana; SQ Innovation; Tenex; Vifor Grant Support/Research Contract - Innolife Faculty Attest that clinical recommendations are evidence-based and free of commercial bias (e.g., peer-reviewed literature, adhering to evidence-based practice guidelines)
Gray, William Yes Grant Support/Research Contract - Conformal; Edwards Lifesciences Consultant Fee/Honoraria/Speaker's Bureau - Shockwave; W.L. Gore & Associates; Medtronic; Philips; Contego Medical; ReValve Medical Industry Salary/Salary Support/Employee (full time or part time) - Boston Scientific Corporation Planner Recusal from controlling aspects of planning and content with which there is a financial relationship
Lindenfeld, JoAnn Yes Grant Support/Research Contract - AstraZenca; Sensible Medical; Volumetrix Consultant Fee/Honoraria/Speaker’s Bureau - Abbott; Alleviant Medical; AstraZenca; Boehringer Ingelheim; Boston Scientific Corporation; CVRx; Edwards Lifesciences; Impluse Dynamics; V-Wave Faculty, Planner Recusal from controlling aspects of planning and content with which there is a financial relationship
Muhammad, Kamran Yes Consultant Fee/Honoraria/Speaker's Bureau - Edwards Lifesciences; Abbott; Medtronic Faculty Attest that clinical recommendations are evidence-based and free of commercial bias (e.g., peer-reviewed literature, adhering to evidence-based practice guidelines)
Shah, Sanjiv Yes Consultant Fee/Honoraria/Speaker’s Bureau - Axon Therapies; Axon Therapies; Corvia Medical; Alleviant Medical; Shifamed; Edwards Lifesciences Grant Support/Research Contract - Corvia; Corvia Medical; Alleviant Medical Faculty Attest that clinical recommendations are evidence-based and free of commercial bias (e.g., peer-reviewed literature, adhering to evidence-based practice guidelines)
Van Spall, Harriette Yes Educational Account - Novartis, Boehringer Ingelheim; Grant Support/Research Contract - Heart and Stroke Foundation, CIHR; Consultant Fee/Honoraria/Speaker's Bureau - Baim Institute for Clinical Research, Medtronic; Clinical Trials Events Committee - CardioVascular Research Foundation; Trial Executive Committee Role - Colorado Prevention Center Clinical Research; Advisory Board - Bayer AG; Clinical Trial Executive Committee Role - Medtronic Planner Recusal from controlling aspects of planning and content with which there is a financial relationship


CME Reviewer(s) and Associate Course Directors(s):

Gary S. Mintz, MD - Consultant Fee/Honoraria/Speaker's Bureau - Boston Scientific Corporation; Abbott; SpectraWave.

Grzegorz L. Kaluza, MD, PhD - Grant Support/Research Contract - Terumo Medical Corporation, Bristol-Myers Squibb, Edwards Lifesciences, Reflow Medical, Shape Memory Medical, Occlutech, Lungpacer, InnovHeart, Ancora Heart, Cardiac Implants, Dura Biotech, Mitria, InQB8, Ethicon, R3 Vascular Puzzle Medical, ReCardia, VivaSure, Magenta Medical, Thubrikar Aortic Valve, Cardiovascular Systems, Inc., Acotec Scientific, Microbot, Philips, Zoll, Cook Medical, Medtronic, ReValve Medical, Orchestra Biomed, MicroVention, Takeda Pharmaceuticals, Retriever Medical, Siemens Healthineers, Trisol Medical, IntraTech, Abbott, Bayliss Medical, Dropshot Therapeutics, Abiomed, Autonomix, UltraVet, Meacor, JensCare, Mitre Medical, 3D Systems, TheraHeart, Tonic Medical, M2SP LLC, MagPad LLC.

Thaifa Smith – Nothing to disclose

Yullee Lai – Nothing to disclose.

CRF identifies relevant financial relationships and mitigates them before the activity begins. The CME associate course directors documented that all relevant financial relationships have been mitigated as of 2/6/2024.

 

 

The Cardiovascular Research Foundation ensures that its programs are educational and meet the needs of the target audience. This program was developed without the influence from commercial supporters.

This enduring webcast was supported by Edwards Lifesciences.

 

 

 

We Recommend

Heart Failure